Yong Zhang

Yong Zhang

Auto-generated profile, based on publicly available information

Yong Zhang

University of Southern California

Research Focus & Metrics

Academic Career Length

31Years (1996-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 November 2018 in Journal of the American Chemical Society
Verified
Journal Article
Closed access
QCQinqin Cheng
Qinqin Cheng
XSXiaojing Shi
Xiaojing Shi
MHMenglu Han
Menglu Han
GSGoar Smbatyan
Goar Smbatyan
HLHeinz-Josef Lenz
Heinz-Josef Lenz
YZYong Zhang
Yong Zhang

1 February 2020 in Molecular Therapy
Verified
Journal Article
Open access
XSXiaojing Shi
Xiaojing Shi
QCQinqin Cheng
Qinqin Cheng
THTianling Hou
Tianling Hou
MHMenglu Han
Menglu Han
GSGoar Smbatyan
Goar Smbatyan
YZYong Zhang
Yong Zhang
Exosomes are nanosized membranous vesicles secreted by a variety of cells. Due to their unique and pharmacologically important properties, cell-derived exosome nanoparticles have drawn significant interest for drug development. By genetically modifying exosomes with two distinct types of surface-displayed monoclonal antibodies, we have developed an exosome platform termed synthetic multivalent antibodies retargeted exosome (SMART-Exo) for controlling cellular immunity. Here, we apply this approach to human epidermal growth factor receptor 2 (HER2)-expressing breast cancer by engineering exosomes through genetic display of both anti-human CD3 and anti-human HER2 antibodies, resulting in SMART-Exos dually targeting T cell CD3 and breast cancer-associated HER2 receptors. By redirecting and activating cytotoxic T cells toward attacking HER2-expressing breast cancer cells, the designed SMART-Exos exhibited highly potent and specific anti-tumor activity both in vitro and in vivo. This work demonstrates preclinical feasibility of utilizing endogenous exosomes for targeted breast cancer immunotherapy and the SMART-Exos as a broadly applicable platform technology for the development of next-generation immuno-nanomedicines.

22 June 2022 in Molecular Therapy
Verified
Journal Article
Open access
QCQinqin Cheng
Qinqin Cheng
ZDZhefu Dai
Zhefu Dai
GSGoar Smbatyan
Goar Smbatyan
AEAlan L. Epstein
Alan L. Epstein
HLHeinz-Josef Lenz
Heinz-Josef Lenz
YZYong Zhang
Yong Zhang
Exosomes are cell-derived nanovesicles involved in regulating intercellular communications. In contrast to conventional nanomedicines, exosomes are characterized by unique advantages for therapeutic development. Despite their major successes in drug delivery, the full potential of exosomes for immunotherapy remains untapped. Herein we designed genetically engineered exosomes featured with surfaced-displayed antibody targeting groups and immunomodulatory proteins. Through genetic fusions with exosomal membrane proteins, Expi293F cell-derived exosomes were armed with monoclonal antibodies specific for human T-cell CD3 and epidermal growth factor receptor (EGFR) as well as immune checkpoint modulators, programmed death 1 (PD-1) and OX40 ligand (OX40L). The resulting genetically engineered multifunctional immune-modulating exosomes (GEMINI-Exos) can not only redirect and activate T cells toward killing EGFR-positive triple negative breast cancer (TNBC) cells but also elicit robust anti-cancer immunity, giving rise to highly potent inhibition against established TNBC tumors in mice. GEMINI-Exos represent candidate agents for immunotherapy and may offer a general strategy for generating exosome-based immunotherapeutics with desired functions and properties.

13 September 2019 in Nature Communications
Verified
Journal Article
Open access
PDF file
XZXiao-Nan Zhang
Xiao-Nan Zhang
QCQinqin Cheng
Qinqin Cheng
JCJingwen Chen
Jingwen Chen
ALAlbert T. Lam
Albert T. Lam
YLYanran Lu
Yanran Lu
YZYong Zhang
Yong Zhang
Nicotinamide adenine dinucleotide (NAD+)-dependent ADP-ribosylation plays important roles in physiology and pathophysiology. It has been challenging to study this key type of enzymatic post-translational modification in particular for protein poly-ADP-ribosylation (PARylation). Here we explore chemical and chemoenzymatic synthesis of NAD+ analogues with ribose functionalized by terminal alkyne and azido groups. Our results demonstrate that azido substitution at 3′-OH of nicotinamide riboside enables enzymatic synthesis of an NAD+ analogue with high efficiency and yields. Notably, the generated 3′-azido NAD+ exhibits unexpected high activity and specificity for protein PARylation catalyzed by human poly-ADP-ribose polymerase 1 (PARP1) and PARP2. And its derived poly-ADP-ribose polymers show increased resistance to human poly(ADP-ribose) glycohydrolase-mediated degradation. These unique properties lead to enhanced labeling of protein PARylation by 3′-azido NAD+ in the cellular contexts and facilitate direct visualization and labeling of mitochondrial protein PARylation. The 3′-azido NAD+ provides an important tool for studying cellular PARylation.

12 September 2021 in Biomaterials
Verified
Journal Article
Closed access
QCQinqin Cheng
Qinqin Cheng
ZDZhefu Dai
Zhefu Dai
XSXiaojing Shi
Xiaojing Shi
XDXinping Duan
Xinping Duan
YWYiling Wang
Yiling Wang
YZYong Zhang
Yong Zhang

5 June 2020 in Science Advances
Verified
Journal Article
Open access
PDF file
ZDZhefu Dai
Zhefu Dai
XZXiao-Nan Zhang
Xiao-Nan Zhang
FNFariborz Nasertorabi
Fariborz Nasertorabi
QCQinqin Cheng
Qinqin Cheng
JLJiawei Li
Jiawei Li
YZYong Zhang
Yong Zhang
A new approach is developed for generating site-specific antibody-drug conjugates for targeted therapy.